The $37 valuation points to a 37% upside, certainly a happier state of affairs for our current standing. As posted earlier this morning, Bank of America came out with their $45 valuation. And Oppenheimer Funds came out with their idea yesterday. I'm not sure these numbers were factored into the $37 consensus view as these valuations require time to pull together. My hunch is that the $37 average falls short of reflecting an accurate representation.
Either way, seeing both of these sweet valuations crop up within a matter of hours has me of the belief that Avita is finally moving onto a larger stage as was the goal when the reverse split was initially envisioned. The Covid-19 pandemic as well as political and racially inspired differences have all contributed massively to slowing company-led operations demonstrably. If anything, management is to be commended for managing to come up with record-setting numbers for the most recent quarter. And now we can look forward to long-in-tooth milestones such a ongoing clinicals plus Japan and the vitiligo launch.
Very exciting times for us longs. Key for me personally is to tune out the doubting Thomases. Pardon my humor but I'll choose to be a hard Richard any day over a flaccid Thomas. I may be eighty but I ain't dead.
Market Data 
Markets 
AI
